Shalin Kothari, MD

• Amer Zeidan
• Anna Kress
• Can Cui
• David A. Hafler
• Erin Longbrake
• Etienne Leveille
• Francine Foss
• Giulia Biancon
• Iris Isufi
• Jennifer VanOudenhove
• Lohith Gowda
• Mengyang Di
• Michael Girardi
• Mina Xu
• Natalia Neparidze
• Nikolai Podoltsev
• Rong Wang
• Rory Shallis
• Scott Huntington
• Stephanie Halene
• Stuart Seropian
• Tarsheen Sethi
• Wade Schulz
• Xiaomei Ma
• Yuxin Liu

Drug Resistance; Apoptosis; Lymphoma, Mantle-Cell

• Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023 PMID: 36655436, DOI: 10.3324/haematol.2022.282252.
• Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical ParametersShariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters The Oncologist 2023, 28: 246-251. PMID: 36651837, PMCID: PMC10020806, DOI: 10.1093/oncolo/oyac245.
• Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies.Leveille E, Kothari S, Müschen M. Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies. Blood Cancer Discovery 2022, 4: 8-11. PMID: 36534735, PMCID: PMC9816816, DOI: 10.1158/2643-3230.bcd-22-0180.
• Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based AnalysisDi M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Stempel J, Ma X, Huntington S. Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis Blood 2022, 140: 10904-10906. DOI: 10.1182/blood-2022-164959.
• High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional SeriesEpperla N, Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series Blood 2022, 140: 3839-3841. DOI: 10.1182/blood-2022-157105.
• Postibrutinib relapse outcomes for patients with marginal zone lymphomaEpperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, Sheets J, Weiner DM, Geethakumari P, Kandarpa M, Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover N, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma Blood Advances 2022, 7: 88-91. PMID: 36269847, PMCID: PMC9827027, DOI: 10.1182/bloodadvances.2022008634.
• P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin LymphomaShah H, Vardell V, Zacholski E, Fegley A, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Aqeel S, Borogovac A, Macdougall K, Kothari S, Kress A, Modi D, Travers E, Chilakamarri N, Brem E, Stephens D, Hu B, Fitzgerlad L, Wagner C, Ermann D. P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma HemaSphere 2022, 6: 47-48. PMCID: PMC9621536, DOI: 10.1097/01.hs9.0000890976.21005.88.
• Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan JM, Buitrago-Pocasangre NC, Lele N, Asashima H, Racke MK, Wilson JE, Givens TS, Tomayko MM, Schulz WL, Longbrake EE, Hafler DA, Halene S, Fan R. Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity. BioRxiv : The Preprint Server For Biology 2022 PMID: 36093346, PMCID: PMC9460970, DOI: 10.1101/2022.08.31.506117.
• Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyEpperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.
• Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: A population-based analysisDi M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis RM, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: A population-based analysis Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.
• Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. Journal Of Clinical Oncology 2022, 40: 7554-7554. DOI: 10.1200/jco.2022.40.16_suppl.7554.
• P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMAErmann D, Vardell V, Zacholski E, Fegley A, Modi D, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Aqeel S, Borogovac A, MacDougall K, Kothari S, Kress A, Travers E, Chilakamarri N, Brem E, Fitzgerald L, Wagner C, Hu B, Stephens D, Shah H. P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA HemaSphere 2022, 6: 969-970. PMCID: PMC9431349, DOI: 10.1097/01.hs9.0000847184.45889.7a.
• A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcomeGuney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Boué DR, Schafernak K, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen A, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW. A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome Blood Advances 2022, 6: 3189-3193. PMID: 35157770, PMCID: PMC9131901, DOI: 10.1182/bloodadvances.2021006018.
• Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based AnalysisDi M, Cui C, Kothari S, Zeidan A, Podoltsev N, Neparidze N, Shallis R, Wang R, Ma X, Huntington S. Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis Blood 2021, 138: 182-182. DOI: 10.1182/blood-2021-146417.
• High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US CentersZayac A, Landsburg D, Hughes M, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Seijung Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers Blood 2021, 138: 455-455. DOI: 10.1182/blood-2021-144308.
• Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 CasesLi P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, Xu ML. Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases Frontiers In Oncology 2021, 11: 730503. PMID: 34589432, PMCID: PMC8474637, DOI: 10.3389/fonc.2021.730503.
• Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell LymphomasLee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
• A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell LymphomaMato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.
• Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.
• Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphomaPatel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
• Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphomaTorka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, Barth M, Hernandez‐Ilizaliturri F. Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma EJHaem 2020, 1: 122-132. PMID: 33073261, PMCID: PMC7566777, DOI: 10.1002/jha2.2.
• Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsTorka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics Blood Advances 2020, 4: 253-262. PMID: 31945157, PMCID: PMC6988401, DOI: 10.1182/bloodadvances.2019000875.
• Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphomaTorka, P, Mavis, C, Kothari, S, Belliotti, Gu J, Sundaram S, Barth M, Hernandez-Ilizaliturri FJ. eJHaem. April 2020; 1– 11. https://doi.org/10.1002/jha2.2
• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment FailureEpperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure Blood 2019, 134: 1554-1554. DOI: 10.1182/blood-2019-129199.
• Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?Kothari S, Hillengass J, McCarthy PL, Holstein SA. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter? Current Hematologic Malignancy Reports 2019, 14: 39-46. PMID: 30671912, DOI: 10.1007/s11899-019-0497-7.
• Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab EraGerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era Journal Of Clinical Oncology 2019, 37: 471-480. PMID: 30615550, PMCID: PMC7554677, DOI: 10.1200/jco.18.00690.
• Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic CentersKothari S, Li S, Medeiros L, Ayers E, Landsburg D, Bond D, Maddocks K, Giri A, Hess B, Pham L, Advani R, Liu Y, Barta S, Vose J, Churnetski M, Cohen J, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski A, Lee S, Hill B, Burns T, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri F, Torka P. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers Blood 2018, 132: 451-451. DOI: 10.1182/blood-2018-99-111530.
• Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical ModelsKothari S, Mavis C, Gu J, Hernandez-Ilizaliturri F. Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models Blood 2018, 132: 2942-2942. DOI: 10.1182/blood-2018-99-116510.
• Striking a Happy MediumKothari S, Hernandez-Ilizaliturri F, Torka P. Striking a Happy Medium Journal Of Clinical Oncology 2017, 35: jco.2017.73.983. PMID: 28682685, DOI: 10.1200/jco.2017.73.9839.
• Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment.Kothari S, Sharif-Tabrizi A, Attwood K, Lamonica D, Levine E, George S. Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment. Journal Of Clinical Oncology 2017, 35: e16513-e16513. DOI: 10.1200/jco.2017.35.15_suppl.e16513.
• Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.DeFilippis AP, Chernyavskiy I, Amraotkar AR, Trainor PJ, Kothari S, Ismail I, Hargis CW, Korley FK, Leibundgut G, Tsimikas S, Rai SN, Bhatnagar A. Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. Journal Of Thrombosis And Thrombolysis 2016, 42: 61-76. PMID: 26510751, PMCID: PMC5403145, DOI: 10.1007/s11239-015-1292-5.
• Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.Kothari S, Ud-Din N, Lisi M, Coyle T. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report. Journal Of Medical Case Reports 2016, 10: 176. PMID: 27301488, PMCID: PMC4908805, DOI: 10.1186/s13256-016-0963-y.
• Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature.Kothari S, Herzig G, Slone S, Herzig R. Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature. SpringerPlus 2013, 2: 49. PMID: 23476896, PMCID: PMC3586393, DOI: 10.1186/2193-1801-2-49.
• Resistance To Acinetobacter Is Not Associated With Disposition Among Patients Leaving A Long-Term Acute-Care FacilityArnold F, Kothari S, Harting J. Resistance To Acinetobacter Is Not Associated With Disposition Among Patients Leaving A Long-Term Acute-Care Facility 2012, a6072-a6072. DOI: 10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6072.